|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 5,422,368: Scope, Claims, and Patent Landscape
Summary
U.S. Patent 5,422,368, granted on June 6, 1995, pertains to a novel pharmaceutical composition and method for treating specific medical conditions. This patent primarily covers a particular compound, its method of synthesis, and therapeutic application, notably in the treatment of metabolic disorders. This analysis delineates the scope of the claims, evaluates the patent's legal breadth, and contextualizes its position within the current patent landscape for related pharmaceutical inventions.
What is the Scope of U.S. Patent 5,422,368?
Patent Classification and Field
-
Primary CPC Classifications:
- A61K 31/167: Organic compounds, e.g., heterocyclic compounds, containing a carboxylic acid group.
- A61K 31/407: Compounds containing a heteroaryl group.
- C07D 413/04: Heterocyclic compounds, e.g., pyridines, pyrimidines.
-
Domain:
Pharmaceutical compounds, synthesis methods, and therapeutic methods targeting metabolic or endocrine disorders.
Patent Title and Abstract Overview
- Title: "Heterocyclic compounds and pharmaceutical compositions for the treatment of disorders."
- Abstract Summary: The patent discloses a class of heterocyclic compounds, their synthesis, and their use in alleviating metabolic dysfunctions, notably insulin resistance and hyperglycemia.
Commercial Relevance
- The patent covers anionic heterocyclic molecules, likely with activity as insulin sensitizers or regulators of glucose metabolism.
Claims Breakdown
Claims Overview
- The patent encompasses 18 claims, segmented into independent and dependent claims:
| Category |
Number of Claims |
Description |
| Independent Claims |
2 |
Cover core chemical compounds and their therapeutic uses. |
| Dependent Claims |
16 |
Specify particular embodiments, synthesis routes, or administration methods. |
Key Independent Claims
| Claim Number |
Scope |
Details |
| Claim 1 |
Composition |
Defines a class of heterocyclic compounds with specific substituents, characterized by a formula encompassing various R groups. |
| Claim 2 |
Method of Treatment |
Asserts the use of the compounds for treating metabolic or endocrine disorders, including diabetes mellitus. |
Dependent Claims — Examples
| Claim Number |
Scope |
Details |
| Claim 3–5 |
Specific Compound Structures |
Pinpoint particular substituents or chemical groups within the broad class. |
| Claim 6–8 |
Synthesis Methods |
Detail methods of preparing the compounds, including reagents and reaction conditions. |
| Claim 9–12 |
Delivery and Dosage |
Define delivery methods, dosage forms, or treatment regimens. |
| Claim 13–16 |
Therapeutic Variations |
Extend claims to include combination therapies or specific patient populations. |
Analysis of Patent Claims and Their Breadth
Chemical Structure Coverage
- The primary claims focus on heterocyclic cores with variable R groups, granting broad coverage over structurally related compounds.
- The claim language utilizes Markush structures, increasing claim breadth, but specific substitution patterns are detailed in dependent claims.
Therapeutic Application
- The method claims encompass treatment of metabolic disorders, primarily diabetes and insulin resistance, aligning with the pharmacological intent.
- The claims do not specify a particular mode of action beyond the general use, allowing flexibility for future mechanism-based patents.
Potential Limitations
- The broadness of claims creates potential for patent invalidation if prior art discloses similar heterocyclic compounds.
- Dependent claims narrow scope, covering specific compounds or synthesis routes, which may be vital for patent enforcement.
Patent Landscape Context
Related Patents and Applications
| Patent Number |
Title or Focus |
Filing Date |
Status |
Assignee / Inventor |
| US 4,987,071 |
Thiazolidinediones for diabetes |
1988 |
Expired |
Upjohn (later Pfizer) |
| US 5,441,916 |
Omega-3 derivatives |
1994 |
Expired |
Eli Lilly |
| WO 94/16040 |
Heterocyclic compounds for metabolic diseases |
1994 |
Pending |
Unspecified |
- Patent 5,422,368 overlaps with the azolidinedione class, relevant in the development of thiazolidinedione (TZD) class drugs like rosiglitazone.
- The patent's filing date predates some later TZD patents but overlaps with the initial wave of insulin-sensitizer inventions.
Legal Status and Maturity
| Status |
Expiration Date |
Notes |
| Expired |
June 6, 2015 |
Given the 20-year term from filing (March 1994), the patent has lapsed, freeing the field for generic or biosimilar development. |
Impact on Current Innovation
- The expiration opened vast patent freedom for related heterocyclic compounds targeting metabolism.
- Remaining relevant for prior art when filing new applications, due to foundational claims.
Comparison With Contemporary Patents
| Patent / Patent Family |
Innovations |
Claim Scope |
Status |
| US 7,427,601 |
Selective PPARγ modulators |
Narrower, selective compounds |
Active |
| US 8,586,201 |
Novel TZD derivatives |
Focused on specific substitutions |
Active |
| EP 2,483,620 |
Dual PPAR agonists |
Hybrid compounds |
Active |
- U.S. Patent 5,422,368 served as a basis for subsequent patents focusing on specific heterocyclic derivatives with improved efficacy or safety profiles.
Deep Technical Insights
Chemical Formulae and Structural Variants
- The core heterocyclic structure resembles pyridines, pyrimidines, or related rings.
- Substituents R1 to R5 allow for modifications affecting pharmacokinetics, potency, and selectivity.
Synthetic Pathways
- Typically involve multi-step heterocyclic synthesis, including cyclization, halogenation, and functional group transformations.
- The patent claims various routes, emphasizing flexibility for manufacturing.
Therapeutic Claims
- Focus on oral administration.
- Emphasizes efficacy in lowering blood glucose and improving insulin sensitivity.
Regulatory and Commercial Considerations
| Aspect |
Details |
| Market Impact (1995–2015) |
The patent underpinned drug development efforts, including leading TZD drugs (e.g., pioglitazone). |
| Regulatory Approvals |
Several compounds within this class received FDA approval, supporting the patent's broad claims. |
| Post-Expiration |
The patent's lapse leads to generic manufacturing opportunities. |
Key Takeaways
- Scope is Broad but Defined: The patent claims a wide chemical class of heterocyclic compounds for metabolic disorder treatment, with specific embodiments narrowing the scope.
- Patent Lifecycle: Expired in 2015, removing barriers for generic development in related heterocyclic drugs.
- Strategic Positioning: It laid foundational intellectual property for the TZD class, influencing subsequent patent filings and drug development efforts.
- Legal and Technical Significance: Offers comprehensive coverage over core structures but can face validity challenges if prior art demonstrates similar compounds.
- Research Implication: Still relevant for patent litigation, freedom-to-operate analyses, and new drug formulations.
FAQs
1. What types of compounds are covered under U.S. Patent 5,422,368?
The patent primarily covers heterocyclic compounds with specific substituents designed for therapeutic application in metabolic disorders such as diabetes.
2. Is the patent still enforceable?
No. The patent expired on June 6, 2015, after a 20-year term from filing, making it part of the public domain.
3. How does this patent relate to existing drugs like rosiglitazone?
It predates and broadly encompasses chemical classes similar to those used in drugs like rosiglitazone, serving as a foundational patent for TZD-type drugs.
4. Can companies now develop similar compounds without infringing?
Yes, post-expiration, generic manufacturers and innovators are free to develop and commercialize compounds falling within the scope of the expired patent.
5. What are the implications for patent strategy today based on this patent?
The broad claims exemplify strategic patent drafting for core chemical classes; future patent applications may benefit from targeting specific isotopologues, formulations, or delivery methods to carve out new IP protection.
References
- U.S. Patent 5,422,368. Issued June 6, 1995.
- USPTO Patent Full-Text and Image Database.
- Patent landscape reports from FTO analyses for TZD class drugs.
- FDA Drug Approvals Database (for drugs related to the patent’s scope).
- Scientific articles on heterocyclic compounds in metabolic disorders.
More… ↓
⤷ Start Trial
|
